nach oben

Erschienen in:

01.07.2007 | Original Article

Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice

verfasst von: Jorge G. Gomez-Gutierrez, Kutlu G. Elpek, Roberto Montes de Oca-Luna, Haval Shirwan, H. Sam Zhou, Kelly M. McMasters

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Cervical cancer remains a leading cause of cancer-related mortality in women, particularly in developing countries. The causal association between genital human papilloma virus (HPV) infection and cervical cancer has been firmly established, and the oncogenic potential of certain HPV types has been clearly demonstrated. Vaccines targeting the oncogenic proteins, E6 and E7 of HPV-16 and -18 are the focus of current vaccine development. Previous studies have shown that calreticulin (CRT) enhances the MHC class I presentation of linked peptide/protein and may serve as an effective vaccination strategy for antigen-specific cancer treatment.

Methods

Two replication-deficient adenoviruses, one expressing HPV-16 E7 (Ad-E7) and the other expressing CRT linked to E7 (Ad-CRT/E7), were assessed for their ability to induce cellular immune response and tested for prophylactic and therapeutic effects in an E7-expressing mouse tumor model.

Results

Vaccination with Ad-CRT/E7 led to a dramatic increase in E7-specific T cell proliferation, interferon (IFN)-γ-secretion, and cytotoxic activity. Immunization of mice with Ad-CRT/E7 was effective in preventing E7-expressing tumor growth, as well as eradicating established tumors with long-term immunological memory.

Conclusion

Vaccination with an adenoviral vector expressing CRT-E7 fusion protein represents an effective strategy for immunotherapy of cervical cancer in rodents, with possible therapeutic potential in clinical settings.

Steller MA (2000) Cervical cancer vaccines: progress and prospects. J Soc Gynecol Investig 9:254–264CrossRef

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19PubMedCrossRef

de Villiers EM (1989) Heterogeneity of the human papillomavirus group. J Virol 63:4898–4903PubMed

Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 87:796–802PubMedCrossRef

Pecoraro G, Morgan D, Defendi V (1989) Differential effects of human papillomavirus type 6, 16, and 18 DNAs on immortalization and transformation of human cervical epithelial cells. Proc Natl Acad Sci USA 86:563–567PubMedCrossRef

Barbosa MS, Vass WC, Lowy DR, Schiller JT (1991) In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J Virol 65:292–298PubMed

Munger K, Scheffner M, Huibregtse JM, Howley PM (1992) Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 12:197–217PubMed

Dyson N, Howley PM, Munger K, Harlow E (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934–937PubMedCrossRef

Thomas M, Banks L (1999) Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J Gen Virol 80(Pt 6):1513–1517PubMed

10.

Armstrong DJ, Roman A (1997) The relative ability of human papillomavirus type 6 and human papillomavirus type 16 E7 proteins to transactivate E2F-responsive elements is promoter- and cell-dependent. Virology 239:238–246PubMedCrossRef

11.

Dong YB, Yang HL, Elliott MJ, Liu TJ, Stilwell A, Atienza C Jr, McMasters KM (1999) Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells. Cancer 86:2021–2033PubMedCrossRef

12.

Elliott MJ, Dong YB, Yang H, McMasters KM (2001) E2F-1 up-regulates c-Myc and p14(ARF) and induces apoptosis in colon cancer cells. Clin Cancer Res 7:3590–3597PubMed

13.

Duensing S, Duensing A, Lee DC, Edwards KM, Piboonniyom SO, Manuel E, Skaltsounis L, Meijer L, Munger K (2004) Cyclin-dependent kinase inhibitor indirubin-3′-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene 23:8206–8215PubMedCrossRef

14.

Jansen KU, Shaw AR (2004) Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med 55:319–331PubMedCrossRef

15.

Furumoto H, Irahara M (2002) Human papilloma virus (HPV) and cervical cancer. J Med Invest 49:124–133PubMed

16.

Zhou X, Qian X, Zhao Q, Lu Y, Xiong M (2004) Efficient expression of modified human papillomavirus 16 e6/e7 fusion protein and the antitumor efficacy in a mouse model. Biol Pharm Bull 27:303–307PubMedCrossRef

17.

Li J, Sun Y, Garen A (2002) Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model. Proc Natl Acad Sci USA 99:16232–16236PubMedCrossRef

18.

Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC (2001) Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108:669–678PubMedCrossRef

19.

Zhang L, Tang Y, Akbulut H, Zelterman D, Linton P-J, Deisseroth AB (2003) An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci USA 100(25):15101–15106PubMedCrossRef

20.

Nash PD, Opas M, Michalak M (1994) Calreticulin: not just another calcium-binding protein. Mol Cell Biochem 135:71–78PubMedCrossRef

21.

Conway EM, Liu L, Nowakowski B, Steiner-Mosonyi M, Ribeiro SP, Michalak M (1995) Heat shock-sensitive expression of calreticulin. In vitro and in vivo up-regulation. J Biol Chem 270:17011–17016PubMedCrossRef

22.

Basu S, Srivastava PK (1999) Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med 189:797–802PubMedCrossRef

23.

Spee P, Neefjes J (1997) TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur J Immunol 27:2441–2449PubMedCrossRef

24.

Sadasivan B, Lehner PJ, Ortmann B, Spies T, Cresswell P (1996) Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 5:103–114PubMedCrossRef

25.

Pike SE, Yao L, Setsuda J, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Atreya CD, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G (1999) Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 94:2461–2468PubMed

26.

Kim JW, Hung CF, Juang J, He L, Kim TW, Armstrong DK, Pai SI, Chen PG, Lin CT, Boyd DA, Wu TC (2004) Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther 11:1011–1018PubMedCrossRef

27.

Peng S, Tomson TT, Trimble C, He L, Hung CF, Wu TC (2006). A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther 13:257–265PubMedCrossRef

28.

He Z, Wlazlo AP, Kowalczyk DW, Cheng J, Xiang ZQ, Giles-Davis W, Ertl HC (2000) Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 270:146–161PubMedCrossRef

29.

He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95:2509–2514PubMedCrossRef

30.

Kim TY, Myoung HJ, Kim JH, Moon IS, Kim TG, Ahn WS, Sin JI (2002) Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res 62:7234–7240PubMed

31.

Hsieh CJ, Kim TW, Hung CF, Juang J, Moniz M, Boyd DA, He L, Chen PJ, Chen CH, Wu TC (2004) Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 22:3993–4001PubMedCrossRef

32.

Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ (1997) Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 158:3270–3276PubMed

33.

Jin HS, Park EK, Lee JM, NamKoong SI, Kim DG, Lee YJ, Jun HJ, Han BD, Bae SM, Ahn WS (2005) Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor. Gynecol Oncol 97:559–567PubMedCrossRef

34.

Liu DW, Tsao YP, Hsieh CH, Hsieh JT, Kung JT, Chiang CL, Huang SJ, Chen SL (2000a) Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J Virol 74:9083–9089CrossRef

35.

Sankaranarayanan R, Rajkumar R, Theresa R, Esmy PO, Mahe C, Bagyalakshmi KR, Thara S, Frappart L, Lucas E, Muwonge R, Shanthakumari S, Jeevan D, Subbarao TM, Parkin DM, Cherian J (2004) Initial results from a randomized trial of cervical visual screening in rural south India. Int J Cancer 109:461–467PubMedCrossRef

36.

Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89:12180–12184PubMedCrossRef

37.

Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, Lowy DR, Schiller JT (1993) Efficient self-assembly of human papillomavirus type 16 L1 and L1–L2 into virus-like particles. J Virol 67:6929–6936PubMed

38.

Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92:11553–11557PubMedCrossRef

39.

Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107(1):18–27PubMed

40.

Fernando GJ, Murray B, Zhou J, Frazer IH (1999) Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. Clin Exp Immunol 115:397–403PubMedCrossRef

41.

Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, Wu TC (2001) Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61:3698–3703PubMed

42.

Liu DW, Tsao YP, Kung JT, Ding YA, Sytwu HK, Xiao X, Chen SL (2000b) Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol 74:2888–2894CrossRef

43.

Tillman BW, Hayes TL, DeGruijl TD, Douglas JT, Curiel DT (2000) Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res 60:5456–5463PubMed

44.

Basak S, Eck S, Gutzmer R, Smith AJ, Birebent B, Purev E, Staib L, Somasundaram R, Zaloudik J, Li W, Jacob L, Mitchell E, Speicher D, Herlyn D (2000) Colorectal cancer vaccines: antiidiotypic antibody, recombinant protein, and viral vector. Ann NY Acad Sci 910:237–253PubMedCrossRef

45.

Bessis N, Garcia-Cozar FJ, Boissier MC (2004) Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 11(Suppl 1):S10–17PubMedCrossRef

46.

Kajiwara K, Byrnes AP, Ohmoto Y, Charlton HM, Wood MJ, Wood KJ (2000) Humoral immune responses to adenovirus vectors in the brain. J Neuroimmunol 103:8–15PubMedCrossRef

47.

Kuzmin AI, Galenko O, Eisensmith RC (2001) An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors. Mol Ther 3:293–301PubMedCrossRef

48.

Gahery-Segard H, Juillard V, Gaston J, Lengagne R, Pavirani A, Boulanger P, Guillet JG (1997) Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts. Eur J Immunol 27:653–659PubMedCrossRef

49.

Lasarte JJ, Corrales FJ, Casares N, Lopez-Diaz de Cerio A, Qian C, Xie X, Borras-Cuesta F, Prieto J (1999) Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide. J Immunol 162:5270–5277PubMed

50.

Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, Olague C, Sola J, Sadaba B, Lacasa C, Melero I, Qian C, Prieto J (2004) Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22:1389–1397PubMedCrossRef

51.

Cordier Kellerman L, Valeyrie L, Fernandez N, Opolon P, Sabourin JC, Maubec E, LeRoy P, Kane A, Legrand A, Abina MA, Descamps V, Haddada H (2003) Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma. Cancer Gene Ther 10:481–490PubMedCrossRef

52.

Hu Z, Garen A (2000) Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci USA 97:9221–9225PubMedCrossRef

53.

Bramson JL, Hitt M, Gauldie J, Graham FL (1997) Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 4:1069–1076PubMedCrossRef

54.

Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE (1998) Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90:1894–1900PubMedCrossRef

55.

Zhi Y, Figueredo J, Kobinger GP, Hagan H, Calcedo R, Miller JR, Gao G, Wilson JM (2006) Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther 17:500–506PubMedCrossRef

56.

Mack CA, Song WR, Carpenter H, Wickham TJ, Kovesdi I, Harvey BG, Magovern CJ, Isom OW, Rosengart T, Falck-Pedersen E, Hackett NR, Crystal RG, Mastrangeli A (1997) Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 8:99–109PubMed

57.

Ueno H, Li JJ, Tomita H, Yamamoto H, Pan Y, Kanegae Y, Saito I, Takeshita A (1995) Quantitative analysis of repeat adenovirus-mediated gene transfer into injured canine femoral arteries. Arterioscler Thromb Vasc Biol 15:2246–2253PubMed

58.

Scaria A, St George JA, Gregory RJ, Noelle RJ, Wadsworth SC, Smith AE, Kaplan JM (1997) Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Gene Ther 4:611–617PubMedCrossRef

59.

Seiler P, Brundler MA, Zimmermann C, Weibel D, Bruns M, Hengartner H, Zinkernagel RM (1998) Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization. J Exp Med 187:649–654PubMedCrossRef

60.

Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B, Economou JS (1998) Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol 161:5607–5613PubMed

61.

Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, Roberts BL (1999) Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 163:699–707PubMed

Titel: Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice
verfasst von: Jorge G. Gomez-Gutierrez
Kutlu G. Elpek
Roberto Montes de Oca-Luna
Haval Shirwan
H. Sam Zhou
Kelly M. McMasters
Publikationsdatum: 01.07.2007
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 7/2007
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-006-0247-2

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2007

Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression

A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients

Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110

Oral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinoma

MIP3 alpha stimulates the migration of Langerhans cells in models of human papillomavirus (HPV)-associated (pre)neoplastic epithelium

Mannan-binding lectin (MBL) in women with tumours of the reproductive system

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie